The present disclosure provides a pharmaceutical composition for multi-stage release of psychoactive substances including cannabinoids. The pharmaceutical composition comprises two or more staged compositions having different release profiles or different release time such that the one or more active agents in each of the two or more staged compositions are released into the subject's blood stream at different time points.

Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.

Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.

The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Crystallized cannabis extract having a purple color is made by first providing cannabis having a detectable amounts of tetrahydrocannabinolic acid (THCA) as well as secondary components including terpenes. Pentane or other solvent is added to the cannabis material to dissolve the secondary components. The cannabis material is enclosed in a filter basket, or a rosin press filter bag, having an average pore diameter of 25 microns. The centrifuge spins the filter bag or filter basket to separate the THCA from the cannabis material and thereby yielding a primary product that is a concentrated cannabis material having at least 95% THCA and a secondary product (high terpene extract) having combined THCA and secondary components including terpenes. The concentrated cannabis material is distilled in a wiped film evaporator or a short path evaporator to oxidize the concentrated cannabis material and yield a super concentrated cannabis material having at least 98% THC.

Crystallized cannabis extract having a purple color is made by first providing cannabis having a detectable amounts of tetrahydrocannabinolic acid (THCA) as well as secondary components including terpenes. Pentane or other solvent is added to the cannabis material to dissolve the secondary components. The cannabis material is enclosed in a filter basket, or a rosin press filter bag, having an average pore diameter of 25 microns. The centrifuge spins the filter bag or filter basket to separate the THCA from the cannabis material and thereby yielding a primary product that is a concentrated cannabis material having at least 95% THCA and a secondary product (high terpene extract) having combined THCA and secondary components including terpenes. The concentrated cannabis material is distilled in a wiped film evaporator or a short path evaporator to oxidize the concentrated cannabis material and yield a super concentrated cannabis material having at least 98% THC.

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

Methods of treating a gastrointestinal spasm in a subject are provided. The methods can include administering an effective amount of a formulation to treat the gastrointestinal spasm, the formulation having a tannin combined with a hydrogen donor in a pharmaceutically acceptable excipient as a binding pair, the tannin releasing in an oxidized state from the hydrogen donor after oral administration of the formulation in the subject; wherein, the composition at least inhibits a gastrointestinal spasm in the subject when compared to a second subject in a control group in which the composition was not administered.

Methods of treating a gastrointestinal spasm in a subject are provided. The methods can include administering an effective amount of a formulation to treat the gastrointestinal spasm, the formulation having a tannin combined with a hydrogen donor in a pharmaceutically acceptable excipient as a binding pair, the tannin releasing in an oxidized state from the hydrogen donor after oral administration of the formulation in the subject; wherein, the composition at least inhibits a gastrointestinal spasm in the subject when compared to a second subject in a control group in which the composition was not administered.

Methods of treating a gastrointestinal spasm in a subject are provided. The methods can include administering an effective amount of a formulation to treat the gastrointestinal spasm, the formulation having a tannin combined with a hydrogen donor in a pharmaceutically acceptable excipient as a binding pair, the tannin releasing in an oxidized state from the hydrogen donor after oral administration of the formulation in the subject; wherein, the composition at least inhibits a gastrointestinal spasm in the subject when compared to a second subject in a control group in which the composition was not administered.